Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
05:15am, Sunday, 30'th Nov 2025
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9 - , 30 - , and 60-fold higher
BEIJING , Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
01:49pm, Tuesday, 25'th Nov 2025
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product of
Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention
12:39pm, Tuesday, 25'th Nov 2025
Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs
There's still hope GLP-1 drugs could slow the second-biggest type of dementia
04:57pm, Monday, 24'th Nov 2025
Can GLP-1s treat vascular dementia? One study failed, but some researchers are holding out hope.
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?
12:35pm, Monday, 24'th Nov 2025
Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by Medicare.
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in the health, safety and rapid
Hims & Hers: The Growth Story Is Outside GLP-1s
08:23am, Monday, 24'th Nov 2025
Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization
Novo Nordisk's oral GLP-1 drug didn't work on Alzheimer's as hoped, and the stock tumbles
07:30am, Monday, 24'th Nov 2025
Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer's.
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
04:30am, Sunday, 23'rd Nov 2025
Novo Nordisk has lost ground in the weight-loss drug market to Eli Lilly and telehealth companies. The company's new CEO is being far more aggressive, which bodes well.
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
06:13pm, Saturday, 22'nd Nov 2025
Eli Lilly is currently the leader in the field and still has strong momentum. Novo Nordisk has made some moves that it hopes will help it catch up.
Is GLP-1 the new AI? Drugmaker Eli Lilly briefly joined the $1 trillion market cap club.
10:40am, Friday, 21'st Nov 2025
Eli Lilly briefly crossed the $1 trillion market cap threshold, the first drug maker to ever reach that milestone.
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
08:06am, Thursday, 20'th Nov 2025
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 blockbusters.
Focus: High-stakes Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit
06:04am, Thursday, 20'th Nov 2025
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progre
Researchers move closer to matching patients with GLP-1 drug that works best for them
05:59pm, Wednesday, 19'th Nov 2025
U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amo
